Lbmc Investment Advisors LLC Grows Position in Eli Lilly and Company $LLY

Lbmc Investment Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 92.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 3,470 shares of the company’s stock after purchasing an additional 1,670 shares during the period. Lbmc Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $2,648,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after purchasing an additional 1,183,038 shares during the period. Laurel Wealth Advisors LLC raised its holdings in shares of Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after buying an additional 11,537,661 shares during the last quarter. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the second quarter worth about $8,827,714,000. Jennison Associates LLC grew its holdings in shares of Eli Lilly and Company by 4.3% during the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after buying an additional 226,620 shares during the last quarter. Finally, Alliancebernstein L.P. grew its holdings in shares of Eli Lilly and Company by 7.9% during the first quarter. Alliancebernstein L.P. now owns 5,443,919 shares of the company’s stock worth $4,496,187,000 after buying an additional 397,696 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 1.2%

Eli Lilly and Company stock opened at $1,042.06 on Thursday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99. The company has a market cap of $985.14 billion, a PE ratio of 50.98, a price-to-earnings-growth ratio of 1.32 and a beta of 0.37. The stock’s 50 day moving average price is $951.95 and its 200 day moving average price is $826.51.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the business posted $1.18 earnings per share. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Wall Street Analyst Weigh In

Several analysts have commented on the company. The Goldman Sachs Group upped their price objective on Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a research note on Monday. Daiwa Capital Markets set a $1,230.00 target price on Eli Lilly and Company and gave the company a “buy” rating in a report on Tuesday. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. Bank of America lowered their price objective on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Loop Capital set a $950.00 price objective on shares of Eli Lilly and Company in a research note on Monday, November 10th. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $1,141.73.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.